EPIQ Partners’s BlackRock Health Sciences Trust II BMEZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-103,000
Closed -$1.48M 70
2023
Q3
$1.48M Sell
103,000
-15,052
-13% -$235K 1.12% 29
2023
Q2
$1.94M Sell
118,052
-16,137
-12% -$263K 1.32% 26
2023
Q1
$2.24M Sell
134,189
-12,260
-8% -$197K 1.55% 24
2022
Q4
$2.26M Sell
146,449
-20,652
-12% -$320K 1.5% 28
2022
Q3
$2.5M Buy
167,101
+1,407
+0.8% +$23.3K 1.54% 25
2022
Q2
$2.72M Sell
165,694
-9,248
-5% -$159K 1.67% 24
2022
Q1
$3.51M Buy
174,942
+15,311
+10% +$318K 1.89% 18
2021
Q4
$4.05M Buy
159,631
+281
+0.2% +$7.25K 2.16% 13
2021
Q3
$4.3M Sell
159,350
-11,000
-6% -$315K 1.98% 13
2021
Q2
$4.93M Buy
170,350
+1,100
+0.6% +$30.4K 2.47% 8
2021
Q1
$4.45M Buy
169,250
+25,375
+18% +$720K 2.55% 8
2020
Q4
$4.12M Buy
143,875
+9,900
+7% +$263K 2.87% 8
2020
Q3
$3.28M Buy
133,975
+6,250
+5% +$144K 2.47% 9
2020
Q2
$2.67M Buy
127,725
+67,350
+112% +$1.33M 2.44% 11
2020
Q1
$1.08M Buy
+60,375
New +$1.16M 1.2% 36

Other funds holding BMEZ

EPIQ Partners's BMEZ Position: Q4 2023 in Review

EPIQ Partners sold out of BlackRock Health Sciences Trust II (BMEZ) in Q4 2023, closing a stake of 103,000 shares — an estimated $1.48M sold.

EPIQ Partners first reported a position in BMEZ in Q1 2020 and held it in 15 quarters. The position peaked at $4.93M in Q2 2021. 105 funds tracked by Wall St. Rank hold BMEZ as of Q4 2023.

  • EPIQ Partners reported no remaining BlackRock Health Sciences Trust II position as of Q4 2023 after selling out during the quarter.
  • EPIQ Partners sold 103,000 BlackRock Health Sciences Trust II shares in Q4 2023, an estimated $1.48M.
  • EPIQ Partners first reported a position in BlackRock Health Sciences Trust II in Q1 2020 and held it in 15 quarters.
  • EPIQ Partners's BlackRock Health Sciences Trust II position peaked at $4.93M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust II as of Q4 2023.

Based on EPIQ Partners's 13F filing for Q4 2023, filed 11 Jan 2024.